An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia

Journal of Antimicrobial Chemotherapy

Volumn 57, Issue 2, 2006, Pages 317-325

  Glasmacher, Axel ^a   Cornely, Oliver ^b   Ullmann, Andrew J ^c   Wedding, Ulrich ^d   Bodenstein, Heinrich ^e   Wandt, Hannes ^f   Boewer, Christian ^g   Pasold, Rita ^h   Wolf, Hans Heinrich ⁱ   Hánel, Mathias ^j   Dölken, Gottfried ^k   Junghanss, Christian ^l   Andreesen, Reinhard ^m   Bertz, Hartmut ⁿ   Höffken, Klaus ^o   Freund, M ^l   Anger, G ^p   Baldus, M ^p   Behringer, D ^p   Berger, D ^p   Bethge, W ^p   Boack, M ^p   Boissevain, F ^p   Breywisch, F ^p   Brockhaus, U ^p   Buechele, T ^p   Clemens, M ^p   Derwahl, K M ^p   Daskalakis, M ^p   Edinger, M ^p   Einsele, H ^p   Fauser, A ^p   Fatkenheuer G ^p   Fetscher, S ^p   Fiedler, F ^p   Fischer, T ^p   Fuchs, S ^p   Gnad, M ^p   Goettler, B ^p   Grote Kiehn, ^p   Happel, ^p   Harder, H ^p   Helbig, W ^p   Hellwig, A ^p   Henrig, D ^p   Hirt, ^p   Huber, Chr ^o   Hutzschenreuter, U ^p   Immenschuh, P ^p   Junghanss, C ^p   Kiefer, T ^p   Koehler, L ^p   Kropmanns, M ^p   Lampe, H ^p   Langer, W ^p   Liebmann, A ^p   Meuter, ^p   Mewes, D ^p   Mezger, J ^p   Mertelsmann, R ^p   Milczynski, C ^p   Moelle, M ^p   Oldenkott, B ^p   Pahnke, R ^p   Pielken, H ^p   Reuter, K ^p   Richter, A ^p   Rost, A ^p   Rothmmann, F ^p   Rudolphi, M ^p   Saal, J ^p   Schaefer Eckart, K ^p   Schmoll, H J ^p   Schoeber, C ^p   Schuler, U ^p   Schultze, W ^p   Schulze, A ^p   Schwenke, G ^p   Skibbe, T ^p   Spyridonidis, A ^p   Steinhauer, H ^p   Stock, J ^p   Teich, M ^p   Theil, E ^p   Theis Menzel, A ^p   Timmer, H ^p   Uebelacker, R ^p   Von Poblozki, A ^p   Weiler, S ^p   Westerhausen, M ^p   Wilhelm, M ^p   Wolf, H H ^p   Wolf, H ^p   Zscherpel, H ^p   more..

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^e KLINIKUM MINDEN   (Germany)

^f KLINIKUM NÜRNBERG   (Germany)

^g St Hedwig Hospital   (Germany)

^h KLINIKUM ERNST VON BERGMANN   (Germany)

ⁱ MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^j KLINIKUM CHEMNITZ   (Germany)

^k UNIVERSITY OF GREIFSWALD   (Germany)

^l UNIVERSITY OF ROSTOCK   (Germany)

^m UNIVERSITY OF REGENSBURG   (Germany)

ⁿ UNIVERSITY OF FREIBURG   (Germany)

^o JENA UNIVERSITY HOSPITAL   (Germany)

^p Universität Rostock ^*

more..

Author keywords

Antifungal Prophylaxis; Aspergillosis; Candidiasis; Invasive fungal infections; Survival

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; ITRACONAZOLE; LIVER ENZYME; NYSTATIN;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE DURATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEART FAILURE; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERKALEMIA; HYPOKALEMIA; HYPONATREMIA; ISCHEMIA; LIVER TOXICITY; LUNG INSUFFICIENCY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MYCOSIS; NAUSEA; NEUTROPENIA; OPEN STUDY; PARALLEL DESIGN; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SKIN DEFECT; TREATMENT OUTCOME; VOMITING;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; ASPERGILLOSIS; DOUBLE-BLIND METHOD; ENDPOINT DETERMINATION; FEMALE; FLUCONAZOLE; HEMATOLOGIC NEOPLASMS; HUMANS; ITRACONAZOLE; LEUKOCYTE COUNT; MALE; MIDDLE AGED; MYCOSES; NEUTROPENIA; NEUTROPHILS;

EID: 31544444209     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dki440     Document Type: Article

References (38)

1. Prentice HG, Kibbler CC, Prentice AG. Towards a targeted, risk-based, antifungal strategy in neutropenic patients. Br J Haematol 2000; 110: 273-84.
2. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32: 358-66.
3. Viscoli C, Girmenia C, Marinus A et al. Candidemia in cancer patients: A prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 1999; 28: 1071-9.
4. Marr KA, Seidel K, White TC et al. Candidemia in allogeneic blood and marrow transplant recipients: Evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000; 181: 309-16.
5. Maertens J, van Eldere J, Verhaegen J et al. Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients. J Infect Dis 2002; 186: 1297-306.
6. Caillot D, Casasnovas O, Bernard A et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 1997; 15: 139-47.
7. Ascioglu S, Rex JH, de Pauw B et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus. Clin Infect Dis 2002; 34: 7-14.
8. Link H, Bohme A, Cornely OA et al. Antimicrobial therapy of unexplained fever in neutropenic patients - guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Intenventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society). Ann Hematol 2003; 82 Suppl 2: S105-S117.
9. McLintock LA, Jordanides NE, Allan EK et al. The use of a risk group stratification in the management of invasive fungal infection: A prospective validation. Br J Haematol 2004; 124: 403-4.
10. Glasmacher A, Prentice AG, Gorschluter M et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for haematological malignancies: Evidence from a meta-analysis of 3,597 patients. J Clin Oncol 2003; 21: 4615-26.
11. Annaloro C, Oriani A, Tagliaferri E et al. Efficacy of different prophylactic antifungal regimens in bone marrow transplantation. Haematologica 1995; 80: 512-7.
12. Huijgens PC, Simoons-Smit AM, van Loenen AC et al. Fluconazole versus itraconazole for the prevention of fungal infections in haemato-oncology. J Clin Pathol 1999; 52: 376-80.
13. Morgenstern GR, Prentice AG, Prentice HG et al. A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group. Br J Haematol 1999; 105: 901-11.
14. Winston DJ, Maziarz RT, Chandrasekar PH et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 2003; 138: 705-13.
15. Marr KA, Crippa F, Leisenring W et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004; 103: 1527-33.
16. Glasmacher A, Prentice AG. Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies. J Antimicrob Chemother 2005; 56 Suppl S1:i23-32.
17. Vreugdenhil G, Van Dijke BJ, Donnelly JP et al Efficacy of itraconazole in the prevention of fungal infections among neutropenic patients with hematologic malignancies and intensive chemotherapy. A double blind, placebo controlled study. Leuk Lymphoma 1993; 11: 353-8.
18. Harousseau JL, Dekker A, Stamatoullas-Bastard A et al. Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: A randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B. Antimicrob Agents Chemother 2000; 44: 1887-93.
19. Menichetti F, Del Favero A, Martino P et al. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: A randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell' Adulto. Clin Infect Dis 1999; 28: 250-5.
20. Nucci M, Biasoli I, Akiti T et al. A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients. Clin Infect Dis 2000; 30: 300-5.
21. Kaptan K, Ural AU, Cetin T et al. Itraconazole is not effective for the prophylaxis of fungal infections in patients with neutropenia: J Infect Chemother 2003; 9: 40-5.
22. Bow EJ, Laverdiere M, Lussier N et al. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: A meta analysis of randomized-controlled clinical trials. Cancer 2002; 94: 3230-46.
23. Kamaluddin M, McNally P, Breatnach F et al. Potentiation of vincristine toxicity by itraconazole in children with lymphoid malignancies. Acta Paediatr 2001; 90: 1204-7.
24. Böhme A, Ganser A, Hoelzer D. Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL. Ann Hematol 1995; 71: 311-2.
25. Gillies J, Hung KA, Fitzsimons E et al. Severe vincristine toxicity in combination with itraconazole. Clin Lab Haematol 1998; 20: 123-4.
26. Marr KA, Leisenring W, Crippa F et al. Cyclophosphamide metabolism is affected by azole antifungals. Blood 2004; 103: 1557-9.
27. Colburn DE, Giles FJ, Oladovich D et al. In vitro evaluation of cytochrome P450-mediated drug interactions between cytarabine, idarubicin, itraconazole and caspofungin. Hematology 2004; 9: 217-21.
28. Nucci M, Biasoli I, Akiti T et al. A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients. Clin Infect Dis 2000; 30: 300-5.
29. Boogaerts M, Maertens J, van Hoof A et al. Itraconazole versus amphotericin B plus nystatin in the prophylaxis of fungal infections in neutropenic cancer patients. J Antimicrob Chemother 2001; 48: 97-103.
30. Marr KA, Leisenring W, Crippa F et al. Cyclophosphamide metabolism is affected by azole antifungals. Blood 2004; 103: 1557-9.
31. Buggia I, Zecca M, Alessandrino EP et al. Itraconazole can increase systemic exposure to busulfan in patients given bone marrow transplantation. GITMO (Gruppo Italiano Trapianto di Midollo Osseo). Anticancer Res 1996; 16: 2083-8.
32. Prentice AG, Glasmacher A. Making sense of itraconazole pharmacokinetics. J Antimicrob Chemother 2005; 56 Suppl S1: I17-22.
33. Prentice AG, Warnock DW, Johnson SA et al. Multiple dose pharmacokinetics of an oral solution of itraconazole in patients receiving chemotherapy for acute myeloid leukaemia. J Antimicrob Chemother 1995; 36: 657-63.
34. Prentice AG, Warnock DW, Johnson SA et al. Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients. J Antimicrob Chemother 1994; 34: 247-52.
35. Glasmacher A, Hahn C, Molitor E et al. Itraconazole trough levels in antifungal prophylaxis with six different dosing regimens using hydroxypropyl-cyclodextrin oral solution or coated-pellet capsules. Mycoses 1999; 42: 591-600.
36. Glasmacher A, Hahn C, Leutner C et al. Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole. Mycoses 1999; 42: 443-51.
37. Glasmacher A, Hahn C, Molitor E et al. Minimal effective trough concentrations for antifungal prophylaxis with itraconazole: A case - control study. In: Abstracts of the Forty-second Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 2002. Abstract M-890, p. 393. American Society for Microbiology, Washington, DC, USA.
38. Boogaerts M, Winston DJ, Bow EJ et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med 2001; 135: 412-22.